(Q33710753)

English

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

28 July 2017

Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. (English)

1 reference

Europe PubMed Central

28 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Suzanne E Dahlberg

1

1 reference

Europe PubMed Central

28 July 2017

Alan B Sandler

2

1 reference

Europe PubMed Central

28 July 2017

Julie R Brahmer

3

1 reference

Europe PubMed Central

28 July 2017

Joan H Schiller

4

1 reference

Europe PubMed Central

28 July 2017

David H Johnson

5

1 reference

Europe PubMed Central

28 July 2017

language of work or name

0 references

publication date

19 January 2010

1 reference

Europe PubMed Central

28 July 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

28 July 2017

28

1 reference

Europe PubMed Central

28 July 2017

949-954

1 reference

Europe PubMed Central

28 July 2017

6

1 reference

Europe PubMed Central

28 July 2017

Intricacies of bevacizumab-induced toxicities and their management

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834434

28 July 2018

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834434

28 July 2018

Management of hypertension in angiogenesis inhibitor-treated patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834434

28 July 2018

Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834434

28 July 2018

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834434

28 July 2018

Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834434

28 July 2018

Mechanisms of adverse effects of anti-VEGF therapy for cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834434

28 July 2018

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834434

28 July 2018

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834434

28 July 2018

Angiogenic growth factors and hypertension

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834434

28 July 2018

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834434

28 July 2018

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834434

28 July 2018

Angiogenesis in cancer, vascular, rheumatoid and other disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834434

28 July 2018

A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834434

28 July 2018

Analysis of survival by tumor response.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834434

28 July 2018

Hypertension and clinical benefit of bevacizumab in the treatment of advanced renal cell carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834434

30 October 2018

Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834434

30 October 2018

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834434

30 October 2018

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834434

30 October 2018

Vascular endothelial growth factor/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834434

30 October 2018

Comparing survival of responders and nonresponders after treatment: a potential source of confusion in interpreting cancer clinical trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834434

30 October 2018

Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2834434

30 October 2018

Reporting results from chemotherapy trials. Does response make a difference in patient survival?

1 reference

https://pubmed.ncbi.nlm.nih.gov/20085937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Analysis and interpretation of the comparison of survival by treatment outcome variables in cancer clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/20085937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/20085937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The structural basis of hypertension: vascular remodelling, rarefaction and angiogenesis/arteriogenesis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20085937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Angiogenesis inhibitors and hypertension: an emerging issue

1 reference

https://pubmed.ncbi.nlm.nih.gov/20085937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypertension as a predictive factor of Sunitinib activity

1 reference

https://pubmed.ncbi.nlm.nih.gov/20085937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker?

1 reference

https://pubmed.ncbi.nlm.nih.gov/20085937

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2009.25.4482

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

1 reference

Europe PubMed Central

28 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33710753&oldid=1990984304"